Press Release
<< Back
Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
“Over the past couple of years, exciting data have emerged from several
research groups demonstrating the importance of FAK inhibition in the
immuno-oncology arsenal,” said Dr.
The
Details for the Immunotherapy World 2016 events are as follows:
Oral Presentation
Title: FAK Inhibitors induce T cell-mediated tumor regression: Prospects for combination with checkpoint inhibitors
Date and time:
Session: Focus Session 3: Next generation approaches to Immuno-oncology: Investigative Therapies, Tools and Tech
A copy of the oral presentation will be available following the presentation at http://bit.ly/R3M6wc
Title: Moving beyond the first generation of immunotherapies
Date and time:
Session: Focus Session 3: Next generation approaches to Immuno-oncology: Investigative Therapies, Tools and Tech
About Focal Adhesion Kinase
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and metastatic capability. VS-6063 (defactinib) and VS-4718 are orally available compounds designed to target cancer stem cells through the potent inhibition of FAK. Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 and VS-4718 are currently being studied in multiple clinical trials for their ability to improve patient survival through the targeting of cancer stem cells, potentiation of an immune response against cancer cells and reduction of the stromal density encapsulating a tumor.
About
This press release includes forward-looking statements about Verastem’s
strategy, future plans and prospects, including statements regarding the
development and activity of Verastem’s product candidates, VS-6063,
VS-4718 and VS-5584, and Verastem’s FAK, PI3K/mTOR and diagnostics
programs generally, the utility of FAK inhibitors for the treatment of
cancer, the timeline for clinical development and regulatory approval of
our product candidates, the structure of our planned or pending clinical
trials, our rights to develop or commercialize our product candidates
and our ability to finance contemplated development activities and fund
operations for a specified period. The words “anticipate,” “appear,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of Verastem’s product candidates and preliminary or
interim data from clinical trials may not be predictive of the results
or success of ongoing or later clinical trials, that data may not be
available when we expect it to be, that enrollment of clinical trials
may take longer than expected, that our product candidates will cause
unexpected safety events, that
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121006447/en/
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com